What do systematic reviews say?

Proportion of people with serious adverse events · acute exacerbations of chronic obstructive pulmonary disease

Adverse events (randomisation to post‐treatment) · children and adolescents with anxiety disorders

Adverse events (randomisation to post‐treatment) · children and adolescents with anxiety disorders

Adverse events (randomisation to post‐treatment) · children and adolescents with anxiety disorders

Adverse events (randomisation to post‐treatment) · children and adolescents with anxiety disorders

Withdrawals due to adverse events not measured · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Adverse events other than hypoglycaemic episodes

Adverse events other than hypoglycaemic episodes

Participant‐assessed adverse events (short‐term) · people with acne scars

Participant‐assessed adverse events (short‐term) · people with acne scars

WIthdrawals due to Adverse Events ‐ not reported · patients with shoulder pain

Adverse events associated with PET ‐ not reported · Individuals with Hodgkin lymphoma

Adverse events associated with RAT — not measured · Workers in positions with safety‐sensitive functions, other than commercial drivers

Non‐serious adverse events assessed using ICH‐GCP · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy;…

Investigator‐assessed adverse events (short‐term) · people with acne scars

Investigator‐assessed adverse events (short‐term) · people with acne scars

Investigator‐assessed adverse events (short‐term) · people with acne scars

Investigator‐assessed adverse events (short‐term) · people with acne scars

Incidence of serious adverse events ‐ not reported · adults with alopecia areata

Incidence of serious adverse events ‐ not reported · adults with alopecia areata